Jazz Pharmaceuticals price target raised to $147 from $137 at Mizuho

Mizuho analyst Irina Koffler raised her price target for Jazz Pharmaceuticals to $147 from $137 to reflect the recent approval of Sunosi and last night’s positive data in the Phase III trial of JZP-258. However, both of these events were largely expected, Koffler tells investors in a research note. She reiterates a Neutral rating on Jazz Pharmaceuticals.

https://thefly.com/landingPageNews.php?id=2884751